黄精在糖尿病并发症中"异病同治"机制的网络药理学研究OA
Network pharmacology study on mechanisms of Huangjing(Polygonati Rhizoma)in"treating different diseases with the same approach"in diabetic complications
目的 基于网络药理学与分子对接方法,探讨黄精在糖尿病并发症中"异病同治"的分子机制.方法 通过TCMSP数据库获取黄精的活性成分和作用靶点,并采用UniProt数据库进行标准化处理.通过OMIM和GeneCards数据库获取糖尿病心肌病、糖尿病肾病、代谢相关脂肪性肝病、糖尿病周围神经病变和糖尿病视网膜病变的相关靶点,并取交集得到糖尿病并发症的共同靶点.将黄精活性成分靶点和糖尿病并发症靶点取交集,得到黄精治疗糖尿病并发症的靶点.将上述靶点导入STRING数据库进行蛋白质-蛋白质相互作用(PPI)分析,以筛选关键靶点.同时,将上述靶点导入Metascape数据库进行基因本体(GO)和京都基因与基因组百科全书(KEGG)富集分析,以筛选关键通路.最后,通过CB-Dock2 平台进行分子对接,验证黄精活性成分和关键靶点的结合活性.结果 共筛选出 7 个黄精治疗糖尿病并发症的活性成分,包括薯蓣皂苷元、谷甾醇、黄芩素、甘草素、7-羟基-2-(4-羟基苯基)-4-色满酮、(+)-丁香树脂酚-O-β-D-葡萄糖苷、β-谷甾醇.数据库提供了 84 个黄精活性成分靶点和 403 个糖尿病并发症相关靶点,两者取交集后得到 23 个黄精治疗糖尿病并发症的靶点.PPI网络筛选出 6个关键靶点,包括MMP9、肿瘤蛋白 53(TP53)、CASP3、蛋白激酶B1(AKT1)、过氧化物酶体增殖物激活受体γ(PPARG)、环氧合酶-2(PTGS2).GO富集分析显示,生物过程主要涉及细胞凋亡调控、氧化应激反应、小分子代谢调节,分子功能主要涉及泛素连接酶结合和抗氧化活性,细胞组分主要涉及线粒体相关结构和神经元突起细胞质.KEGG富集分析显示,信号通路主要涉及内分泌抵抗、细胞凋亡和白细胞介素(IL)-17 信号通路.分子对接表明,7 种活性成分与上述靶点存在良好的结合活性.结论 本研究筛选出 7 种黄精治疗糖尿病并发症的活性成分,并预测MMP9、TP53、CASP3、AKT1、PPARG、PTGS2 作为黄精在糖尿病并发症中"异病同治"机制的关键靶点,其通路主要涉及内分泌抵抗、细胞凋亡、IL-17 信号通路.
Objective To investigate the molecular mechanisms of Huangjing(Polygonati Rhizoma)in exerting the"treating different diseases with the same approach"effect on diabetic complications based on network pharmacology and molecular docking methods.Methods The active ingredients and related targets of Huangjing(Polygonati Rhizoma)were obtained from the TCMSP database and standardized using the UniProt database.Targets related to diabetic cardiomyopathy,diabetic nephropathy,metabolic dysfunction-associated fatty liver disease,diabetic peripheral neuropathy,and diabetic retinopathy were collected from the OMIM and GeneCards databases,and their intersection was identified to obtain common targets of diabetic complications.Subsequently,the intersection between the active ingredient targets of Huangjing(Polygonati Rhizoma)and diabetic complication targets was derived to obtain the targets of Huangjing(Polygonati Rhizoma)for treating diabetic complications.These targets were then imported into the STRING database for protein-protein interaction(PPI)analysis to screen for key targets.Meanwhile,the targets were also imported into the Metascape database for GO and KEGG enrichment analyses to identify key pathways.Finally,molecular docking was performed using the CB-Dock2 platform to validate the binding affinity between the active ingredients of Huangjing(Polygonati Rhizoma)and the key targets.Results A total of seven active ingredients of Huangjing(Polygonati Rhizoma)for treating diabetic complications were identified,including diosgenin,sitosterol,baicalein,liquiritigenin,(2R)-7-hydroxy-2-(4-hydroxyphenyl)chroman-4-one,(+)-syringaresinol-O-β-D-glucoside,and β-sitosterol.The databases provided 84 targets of active ingredients in Huangjing(Polygonati Rhizoma)and 403 common targets of diabetic complications,with 23 overlapping targets considered potential therapeutic targets.PPI network identified six key targets:MMP9,TP53,CASP3,AKT1,PPARG,and PTGS2.GO enrichment analysis indicated that biological processes were mainly involved in the regulation of apoptosis,oxidative stress response,and small molecule metabolism;molecular functions were mainly associated with ubiquitin ligase binding and antioxidant activity;and cellular components were mainly related to mitochondrial structures and neuronal cytoplasm.KEGG pathway analysis revealed that the targets were primarily enriched in endocrine resistance,apoptosis,and IL-17 signaling pathways.Molecular docking results demonstrated that the seven active ingredients had good binding affinity with the aforementioned targets.Conclusion This study screened out seven active ingredients of Huangjing(Polygonati Rhizoma)for the treatment of diabetic complications,and predicted MMP9,TP53,CASP3,AKT1,PPARG,and PTGS2 as the key targets of Huangjing(Polygonati Rhizoma)in the mechanism of"treating different diseases with the same approach"in diabetic complications.The underlying mechanisms may involve multiple pathways,including endocrine resistance,apoptosis,and IL-17 signaling pathways.
金梦婷;潘伟力;胡方林
湖南中医药大学 中医学院,湖南 长沙 410208||浙江中医药大学附属第三医院 肾病科,浙江 杭州 310005浙江中医药大学附属第三医院 肾病科,浙江 杭州 310005湖南中医药大学 中医学院,湖南 长沙 410208
医药卫生
黄精糖尿病并发症异病同治网络药理学分子对接
Huangjing(Polygonati Rhizoma)diabetic complicationstreating different diseases with the same approachnetwork pharmacologymolecular docking
《药食同源杂志》 2026 (3)
214-223,10
浙江省中医药科技计划项目(2023ZL068).
评论